Mercaptopurin Orion (Mercaptopurine Monohydrate)

Mercaptopurine is converted inside cells to active thio‑guanine nucleotides that block purine synthesis and become incorporated into DNA and RNA. This disrupts nucleic‑acid formation, inhibiting the growth of rapidly dividing cancer cells and dampening immune‑cell proliferation.

The dosage of Mercaptopurin Orion is individualized. A qualified prescriber determines the appropriate amount based on the patient’s condition, weight, renal and hepatic function, and other clinical factors. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for mercaptopurine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their physician.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mercaptopurine is a purine analog that directly interferes with DNA synthesis, whereas other immunosuppressants such as calcineurin inhibitors act on intracellular signaling pathways. Mercaptopurine is often chosen for its oral route and specific efficacy in certain leukemias and inflammatory conditions.

Mercaptopurin Orion should be stored at room temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight and heat sources to maintain stability and potency.

The medication is taken orally, usually as a tablet, with or without food as directed by the prescribing clinician. Swallow the tablet whole with a glass of water and follow any specific timing instructions given by the healthcare provider.

Serious risks include bone‑marrow suppression leading to pancytopenia, severe infections, hepatotoxicity, pancreatitis, allergic reactions such as anaphylaxis, and the rare possibility of secondary malignancies. Patients should be monitored regularly for these complications.

Individuals with known hypersensitivity to mercaptopurine or any component of the formulation should avoid the drug. Patients with severe bone‑marrow failure, uncontrolled infections, or significant liver disease may also be contraindicated, pending clinical assessment.